# The Burden of Long-Term Opioid Use on Emotional, Cognitive and Sensorimotor Domains in Chronic Back Pain

Gaelle Rached MD MSc[1], Andrew D. Vigotsky MS[1], Paulo Branco PhD[1], Rami Jabakhanji PhD[1], Thomas J. Schnitzer MD PhD [1], A. Vania Apkarian PhD [1], Marwan N. Baliki PhD [1]

[1]Center for Translational Pain Research, and Center of Excellence for Chronic Pain and Drug Abuse Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Correspondence to: Dr A.V. Apkarian
E-mail : a-apkarian@northwestern.edu

Word Count: 589

Acknowledgments:
Elizabeth Yan, data collection
Meghan Ford, data collection
Maryam Abdallah, data collection
Byron K Yip, data collection

## Abstract

We evaluated the incremental effect of opioids on chronic back pain patients (CBP) by comparing 50 CBP on opioid therapy (CBP+O; opioid duration ≥ 3 months) to pain intensity-, pain duration-, age-, and sex- matched CBP who were not on opioids (CBP-O). Participants completed the NIH Toolbox's cognitive, affective, sensory, and motor components. Several emotional domains were negatively impacted by opioid usage, and we did not observe any dose- or duration-response relationships within the opioid group. Finally, several domains were similarly disrupted in CBP+O and CBP-O compared to normative data, highlighting the need for CBP-O control groups when studying CBP+O.

## Introduction

The opioid epidemic is a major public health crisis affecting the United States, with devastating health, economic, and societal costs (1). Opioids are widely used for treating chronic pain, contributing to the ongoing epidemic. Prescription opioid misuse and chronic pain independently lead to negative affect and detrimental effects on psychological well-being (2). The cumulative impact of long-term opioid use to manage chronic pain is poorly understood, partly because patients' behavioral and psychological functions have not been characterized in a properly controlled study. Here we investigated the incremental effect of opioids on patients with chronic back pain (CBP) by comparing CBP on long-term opioids (CBP+O) to matched CBP with no opioids (CBP−O). We studied these patients using a standard multidimensional assessment tool, the NIH toolbox, which spans cognitive, emotional, sensory, and motor dimensions. Finally, we examined how opioid dosage and opioid duration impact these four dimensions in the opioid group.

## Methods

We recruited 50 CBP (pain duration > 6 months) who were on opioid therapy for at least three months and 50 CBP who were not on opioids. Patients were matched on age, sex, pain intensity, and duration (Table 1). Northwestern IRB approved the study.

Participants completed NIH Toolbox's cognitive, emotional, sensory, and motor components (Supplementary Methods) (3). Pain intensity (numeric rating scale, NRS) and pain duration were collected for all participants. For the CBP+O group, we collected opioid duration and opioid dosage, which we converted to morphine milligram equivalent (MME) using CDC's conversion factors.

**Table 1: Demographic characteristics in patients with chronic back pain with and without opioids.**

| | **Non-Opioid (n=50)** | **Opioid (n=50)** | ***p*** |
|---|---|---|---|
| Age (years) (Mean (SD)) | 60.56 (13.61) | 58.28 (11.66) | 0.371 |
| Male (%) | 21 (42.0) | 21 (42.0) | 1.000 |
| Pain Intensity - NRS (Mean (SD)) | 6.50 (1.93) | 6.52 (1.95) | 0.959 |
| Pain Duration (years) (Mean (SD)) | 5.25 (13.69) | 17.92 (13.04) | 0.321 |
| Opioid Duration (years) (Mean (SD)) | *NA* | 7.69 (6.14) | *NA* |
| Morphine milligram equivalent (mg/day) MME (Mean (SD)) n-49 | *NA* | 64.67 (207.14) | *NA* |
| Morphine milligram equivalent (mg/day) MME (median +/- IQR) | *NA* | 20 +/- 30 | *NA* |
| Hydrocodone, n (%) | *NA* | 19 (34.5) | *NA* |
| Tramadol, n (%) | *NA* | 17 (30.9) | *NA* |
| Oxycodone, n (%) | *NA* | 9 (16.4) | *NA* |
| Fentanyl, n (%) | *NA* | 2 (3.6) | *NA* |
| Morphine, n (%) | *NA* | 2 (3.6) | *NA* |
| Codeine, n (%) | *NA* | 1 (1.8) | *NA* |
| Oxymorphone, n (%) | *NA* | 1 (1.8) | *NA* |
| Buprenorphine, n (%) | *NA* | 1 (1.8) | *NA* |
| Methadone, n (%) | *NA* | 2 (3.6) | *NA* |

MME was log-transformed due to its skewed distribution; thus, median, and interquartile range (IQR) is also reported.

## Results

Groups' NIH Toolbox outcomes are depicted independently in Figure 1A and contrasted in Figure 1B. CBP+O patients showed more severe negative affect and perceived stress, and lower social satisfaction and worse psychological well-being, compared to CBP−O patients ($P < 0.05$; Figure 1B). CBP+O patients also showed higher pain-interference and lower dominant hand 9-hole pegboard dexterity than CBP−O ($P < 0.001$). Partial correlations within the CBP+O group—adjusted for age, sex, pain duration, and pain intensity—did not reveal any strong or consistent relationships between the NIH Toolbox items and opioid dosage (MME) or opioid duration (Figure 1C,D).




**Figure 1: The emotional, cognitive and sensorimotor scores in patients with chronic back pain with or without long-term opioid use and their relationships with opioid dosage and opioid duration.**

(A) Estimated marginal means (95% CI) of the NIH toolbox components for patients with chronic back pain with (red, *n*=50) and without (blue, *n*=50) long-term opioids. Point estimates and their CIs come from a linear regression adjusted for age, sex, pain intensity, and duration. The grey line indicates the mean in a normative sample (normative T-score = 50 ± 10). Each group can thus be directly compared to the normative sample using their estimate and 95% CI. Data points with CIs excluding the line indicate $P < 0.05$. (B) Group differences (95% CI) for each of the subscales. (C) Partial correlations (95% CI) between the NIH Toolbox items and opioid dosage (log(MME)), adjusted for age, sex, pain intensity, and pain duration. (D) Partial correlations (95% CI) between the NIH Toolbox items and opioid duration (years), adjusted for age, sex, pain intensity, and pain duration.

## Discussion

Our findings can be summarized in three main points. First, and in line with previous research (4), several emotional domains are negatively impacted by opioid usage, while CBP−O's values were similar to a normative population (Figure 1A,B). Second, and consistent with other findings (5), despite poorer outcomes on these scales, we did not detect dose- or duration-response relationships within the opioid group (Figure 1C,D). Together, points one and two show that, regardless of the dose or duration of their prescription, patients with long-term opioids behaviorally and psychologically differ from patients without opioids. These effects are present despite the patient and their prescriptions being clinically overseen by a physician. Although confounding by indication is a possibility, previous work that controls for confounding suggests the relationship between opioid use and depression may be bidirectional: those with depression are more likely to be prescribed opioids and those who are prescribed opioids are more likely to develop depression (6). Thus, our results may represent a conglomeration of these two

possibilities; individuals who are prescribed opioids may differ at baseline, but also, opioids themselves may affect emotional and sensorimotor characteristics. Finally, several domains were similarly disrupted in CBP+O and CBP−O compared to normative data (Figure 1A). This suggests that more general cognitive, sensory, and motor findings are attributable to chronic pain rather than opioids. Together, these findings support the view that opioid treatment, above and beyond the effect of chronic pain itself, places patients at risk of emotional disruption that may affect their well-being.

## References


1. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry. 2021;26(1):218-33.

2. Martel MO, Dolman AJ, Edwards RR, Jamison RN, Wasan AD. The Association Between Negative Affect and Prescription Opioid Misuse in Patients With Chronic Pain: The Mediating Role of Opioid Craving. The Journal of Pain. 2014;15(1):90-100.

3. NIH. NIH Toolbox® Scoring and Interpretation Guide for the iPad: National Institutes of Health and Northwestern University

; 2021 [updated 5/25/2021.

4. Wakaizumi K, Vigotsky AD, Jabakhanji R, Abdallah M, Barroso J, Schnitzer TJ, et al. Psychosocial, Functional, and Emotional Correlates of Long-Term Opioid Use in Patients with Chronic Back Pain: A Cross-Sectional Case-Control Study. Pain Ther. 2021;10(1):691-709.

5. Denawa Y, Kurtz W, Conermann T. The Social and Functional Implications of High-Versus Low-Dose Opioids on Chronic Non-Cancer Pain. Pain Physician. 2019;22(4):401-11.

6. Sullivan MD. Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction. The Clinical Journal of Pain. 2018;34(9):878-84.